论文部分内容阅读
目的:评价对血糖控制不佳的2型糖尿病患者进行瑞格列奈和吡格列酮单药和联合治疗后,糖化血红蛋白(HbAlc)、血脂及蛋白多糖-低密度脂蛋白(PG-LDL)结合力的变化。方法:经过4周标准的糖尿病饮食和运动治疗之后,患者随机进入为期6周的瑞格列奈单药治疗组(1～2mg/d,35例)和吡格列酮单药治疗组(30mg/d,32例),血糖未达标者转入为期12周的2药联合治疗。测定治疗前后的HbAlc和TC、TG、LDL、HDL水平。超离心方法分离血浆LDL,体外测定PG-LDL结合力(数据以每μgPG能够结合多少μgLDL-C来表示)。结果:HbAlc水平在瑞格列奈和吡格列酮单药组及联合组分别为7·14%、7·24%、6·72%,PG-LDL结合力分别为10·9、11·4、7·4,联合组与单药组比较差异有统计学意义。3组TC、TG、LDL、HDL值差异无统计学意义。结论:瑞格列奈和吡格列酮联合治疗能够进一步改善2型糖尿病患者的血糖控制,减少PG-LDL结合力。
PURPOSE: To evaluate the association of glycosylated hemoglobin (HbA1c), lipids, and proteoglycan-low density lipoprotein (PG-LDL) in patients with type 2 diabetes who are poorly controlled by blood glucose after repaglinide and pioglitazone monotherapy and combination therapy Variety. METHODS: After 4 weeks of standard diabetic diet and exercise therapy, patients were randomized to receive either a single dose of repaglinide (35 mg) or a single dose of 30 mg / d of repaglinide 32 cases), blood glucose did not meet the criteria for 12 weeks of 2-drug combination therapy. HbAlc and TC, TG, LDL, HDL levels before and after treatment were measured. Plasma LDL was separated by ultracentrifugation and PG-LDL binding was measured in vitro (data expressed as how many μgLDL-C each μg PG can bind). Results: The levels of HbA1c in the repaglinide and pioglitazone groups were 7.14%, 7.24% and 6.72% respectively, and the binding capacity of PG-LDL was 10.9, 11.4, · 4, the combined group and single drug group differences were statistically significant. There was no significant difference in TC, TG, LDL and HDL between the three groups. Conclusion: The combination of repaglinide and pioglitazone can further improve glycemic control and reduce PG-LDL binding in type 2 diabetic patients.